Thymoglobulin

ApprovedSmall molecule

Sanofi

Thymoglobulin is one of 595 small molecule programs targeting Ischemia Reperfusion Injury. It is currently in Approved.

Indications

Total Trials

Active Trials

594

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemia Reperfusion InjuryActive, not recruiting

Liver TransplantActive, not recruiting

ToxicityActive, not recruiting

Cutaneous T-Cell LymphomaActive, not recruiting

LeukemiaActive, not recruiting

NeuroblastomaActive, not recruiting

Acute Graft Vs. Host DiseaseActive, not recruiting

Kidney TransplantActive, not recruiting

Cardiac TransplantActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Ischemia Reperfusion InjuryApproved

Active, not recruiting

Liver TransplantPhase 2

Active, not recruiting

ToxicityPhase 2

Active, not recruiting

Cutaneous T-Cell LymphomaPhase 2

Active, not recruiting

LeukemiaPhase 1/Phase 2

Active, not recruiting

NeuroblastomaPhase 1

Active, not recruiting

Acute Graft Vs. Host DiseasePreclinical

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

Cardiac TransplantPhase 2

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 2

Active, not recruiting

Showing 10 of 23 indications

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Thymoglobulin

Sanofi

Approved

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Nolvadex

AstraZeneca

Preclinical

1 6

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Abecma

Bristol-Myers Squibb

Preclinical

4 9

Oblimersen Sodium

NNational Cancer Institute (NCI)

Preclinical

2 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Stem Cell Transplant

NCT03219359

Phase 3Not yet recruiting

Acute Myeloid Leukemia

NCT06083129

Q4 2030

Phase 2Recruiting

Transplantation

NCT05735717

Phase 1Recruiting

Memory

NCT07052370

Q2 2032

Phase 2Recruiting

Hemoglobinopathies

NCT06872333

Q4 2038

Phase 2Recruiting

Allogeneic Hematopoietic Cell Transplant

NCT03852407

Clinical

Trials by Indication[1]

Kidney Transplant12 trials

Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)

Unknown status·—·Phase 4·NCT02447822·154 enrolled

Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients

Completed·AAssociação Médico Espírita de Botucatu·Phase 4·NCT02683291·48 enrolled

Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients

Completed·CCoordinación de Investigación en Salud, Mexico·Phase 4·NCT03006419·100 enrolled

Show 9 more trials

Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate

Completed·HHospital do Rim e Hipertensão·Phase 4·NCT01354301·300 enrolled

Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen

Unknown status·HHospital Geral de Fortaleza·Phase 4·NCT03088280·200 enrolled

A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00455013·93 enrolled

Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch

Completed·JJohns Hopkins University·Phase 3·NCT00275509·56 enrolled

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

Withdrawn·UUniversity of Wisconsin, Madison·Phase 4·NCT02130817

A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant

Completed· Amgen logo

Amgen·Phase 2·NCT04046549·25 enrolled

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02495077·290 enrolled

Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00006178·12 enrolled

Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients

Terminated·UUniversity of Pennsylvania··NCT02730715·30 enrolled

Myelodysplastic Syndrome4 trials

Thymoglobulin and Cyclosporine in Patients With Aplastic Anemia or Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00806598·53 enrolled

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT01471444·256 enrolled

Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00402558·15 enrolled

Show 1 more trial

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00475020·63 enrolled

Transplantation4 trials

Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation

Terminated·WWashington University School of Medicine·Phase 2·NCT00593645·7 enrolled

Completed·MMassachusetts General Hospital·Phase 2·NCT00133367·32 enrolled

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT05735717·70 enrolled

Show 1 more trial

Pilot Study of Unrelated Cord Blood Transplantation

Terminated·KKing's College Hospital NHS Trust·Phase 2·NCT00916045·40 enrolled

Renal Transplant4 trials

Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant

Completed·RRonaldo de Matos Esmeraldo, MD·Phase 4·NCT02084446·120 enrolled

Low Dose Thymoglobin in Renal Transplant Patients

Completed·LLahey Clinic·N/A·NCT01280617·44 enrolled

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

Completed·MMassachusetts General Hospital·Phase 2·NCT02464878·2 enrolled

Show 1 more trial

Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin

Completed·MMaimónides Biomedical Research Institute of Córdoba··NCT03147183·150 enrolled

Severe Aplastic Anemia3 trials

The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia

Completed·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT02745717·60 enrolled

Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02224872·18 enrolled

NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02833805·21 enrolled

44 more indications

Renal Transplant Recipients3 trials

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

Completed·UUniversity of Cincinnati·Phase 4·NCT00771745·11 enrolled

Selective CD28 Blockade in Renal Transplant Recipients

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04903054

Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk

Completed·UUniversity Hospital, Lille·Phase 3·NCT00682292·227 enrolled

Acute Myeloid Leukemia3 trials

Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06083129·324 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02441803·11 enrolled

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00469014·72 enrolled

Stem Cell Transplant3 trials

Autologous Stem Cell Transplant for Crohn's Disease

Recruiting·AAaron Etra·Phase 2·NCT03219359·50 enrolled

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00303667·50 enrolled

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00857389·60 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation2 trials

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00990249·120 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00523809·5 enrolled

Thalassemia2 trials

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT04009525·823 enrolled

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT03171831·30 enrolled

Renal Allograft Recipients2 trials

Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients

Terminated·WWashington University School of Medicine·N/A·NCT00235781·90 enrolled

An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.

Completed· Sanofi logo

Sanofi·Phase 2·NCT00235300·240 enrolled

Hematologic Malignancies2 trials

Thymoglobulin and Total Lymphoid Irradiation for Hematologic Malignancies

Completed·MM.D. Anderson Cancer Center·N/A·NCT00476229·20 enrolled

Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies

Terminated·UUniversity of Virginia·Phase 2·NCT01622556·6 enrolled

Stem Cell Transplantation2 trials

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01490723·20 enrolled

Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML

Terminated·NNew York Medical College·Phase 1·NCT00669890·12 enrolled

Liver Transplant2 trials

A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation

Completed·TThe Cleveland Clinic·Phase 2·NCT02544113·110 enrolled

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

Completed· Sanofi logo

Sanofi·Phase 2·NCT00117689·75 enrolled

Donor2 trials

Thymoglobulin in Cadaver Donor

Completed·IInstituto de Investigación Hospital Universitario La Paz·Phase 2·NCT01939171·20 enrolled

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT02582775·17 enrolled

Renal Transplantation2 trials

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation

Completed·UUniversity of Miami·Phase 4·NCT00681343·38 enrolled

Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation

Completed·UUniversity of Miami·Phase 4·NCT00685061·90 enrolled

Sickle Cell Disease1 trial

Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease

Completed·MMonica Bhatia·Phase 1·NCT02867800·24 enrolled

Memory1 trial

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

Recruiting·SSt. Jude Children's Research Hospital·Phase 1·NCT07052370·30 enrolled

Cutaneous T-cell lymphoma1 trial

Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00506129·33 enrolled

Allogeneic Stem Cell Transplantation1 trial

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT02512497·23 enrolled

Acute Graft Versus Host Disease1 trial

Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00506948·13 enrolled

Hemoglobinopathies1 trial

Allo HSCT for High Risk Hemoglobinopathies

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT06872333·62 enrolled

Neuroblastoma1 trial

Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma

Terminated·—·Phase 1·NCT00670410·15 enrolled

Steroid1 trial

Thymoglobulin in Calcineurin Inhibitor and Steroid Minimization Protocol

Unknown status·UUniversity Health Network, Toronto·Phase 4·NCT00706680·30 enrolled

Bone Marrow Transplantation1 trial

Non-Myeloablative Conditioning and Bone Marrow Transplantation

Unknown status·VVanderbilt-Ingram Cancer Center·N/A·NCT01850108·26 enrolled

Leukemia1 trial

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Unknown status·—·Phase 1/2·NCT00679536·30 enrolled

Multiple Myeloma1 trial

A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma

Completed·WWashington University School of Medicine·Phase 1·NCT00545519·6 enrolled

Myeloproliferative Disorder1 trial

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Completed·EEverett Meyer·Phase 2·NCT01392989·44 enrolled

Total Body Irradiation1 trial

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Completed·VVirginia Commonwealth University·Phase 2·NCT00709592·42 enrolled

Chronic Lymphocytic Leukemia1 trial

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00899431·39 enrolled

Toxicity1 trial

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Terminated·EEmory University·Phase 2·NCT02877082·5 enrolled

Trial1 trial

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Terminated·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT02627573·32 enrolled

Age1 trial

Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA

Unknown status·NNagoya University·Phase 3·NCT01844635·320 enrolled

Chronic Myelogenous Leukemia1 trial

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00813124·24 enrolled

Scleroderma1 trial

Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

Terminated·NNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)·Phase 1·NCT00040651·15 enrolled

Acute Graft Vs. Host Disease1 trial

Thymoglobulin to Prevent Acute Graft vs. Host Disease (GvHD) in Patients With Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

Completed· Sanofi logo

Sanofi·N/A·NCT00088543·60 enrolled

Graft Versus Host Disease1 trial

Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC

Terminated·NNantes University Hospital·Phase 2·NCT03263767·47 enrolled

Elderly Patients1 trial

PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM

Not yet recruiting·IInstitut Paoli-Calmettes·Phase 2·NCT06066255·27 enrolled

Tics1 trial

Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants

Terminated·TThe Hospital for Sick Children·Phase 2·NCT01135537·30 enrolled

Renal Transplant Rejection1 trial

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

Completed· Sanofi logo

Sanofi·Phase 2·NCT00089947·150 enrolled

Lung Transplantation1 trial

Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation

Withdrawn·UUniversity of California, Los Angeles·Phase 3·NCT00592306

Ischemia Reperfusion Injury1 trial

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Withdrawn·GGeorgetown University·Phase 4·NCT01149993

T Cell1 trial

Methods of T Cell Depletion Trial (MoTD)

Unknown status·UUniversity of Birmingham·Phase 2·NCT04888741·400 enrolled

Randomized1 trial

Randomized Trial of 2 Antibody Induction Steroid Avoidance Protocols

Completed·UUniversity of Miami·Phase 4·NCT01172418·200 enrolled

Immunosuppression1 trial

rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)

Completed·IInstitute for Clinical and Experimental Medicine·Phase 3·NCT04302805·17 enrolled

Cardiac Transplant1 trial

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Enrolling by invitation·—·Phase 2·NCT03292861·60 enrolled

Cardiac Allograft Vasculopathy1 trial

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

Withdrawn·—·Phase 3·NCT01157949

Allogeneic Hematopoietic Cell Transplant1 trial

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Recruiting·UUniversity of Liege·Phase 2·NCT03852407·114 enrolled

Unspecified1 trial

Regimen Optimization Study

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02137239·58 enrolled

Sources

References

[1]
ClinicalTrials.gov — 85 trial records for Thymoglobulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thymoglobulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thymoglobulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Thymoglobulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q4 2030

Q2 2032

Q4 2038

Trials by Indication[1]

Kidney Transplant12 trials

Myelodysplastic Syndrome4 trials

Transplantation4 trials

Renal Transplant4 trials

Severe Aplastic Anemia3 trials

Renal Transplant Recipients3 trials

Acute Myeloid Leukemia3 trials

Stem Cell Transplant3 trials

Allogeneic Hematopoietic Stem Cell Transplantation2 trials

Thalassemia2 trials

Renal Allograft Recipients2 trials

Hematologic Malignancies2 trials

Stem Cell Transplantation2 trials

Liver Transplant2 trials

Donor2 trials

Renal Transplantation2 trials

Sickle Cell Disease1 trial

Memory1 trial

Cutaneous T-cell lymphoma1 trial

Allogeneic Stem Cell Transplantation1 trial

Acute Graft Versus Host Disease1 trial

Hemoglobinopathies1 trial

Neuroblastoma1 trial

Steroid1 trial

Bone Marrow Transplantation1 trial

Leukemia1 trial

Multiple Myeloma1 trial

Myeloproliferative Disorder1 trial

Total Body Irradiation1 trial

Chronic Lymphocytic Leukemia1 trial

Toxicity1 trial

Trial1 trial

Age1 trial

Chronic Myelogenous Leukemia1 trial

Scleroderma1 trial

Acute Graft Vs. Host Disease1 trial

Graft Versus Host Disease1 trial

Elderly Patients1 trial

Tics1 trial

Renal Transplant Rejection1 trial

Lung Transplantation1 trial

Ischemia Reperfusion Injury1 trial

T Cell1 trial

Randomized1 trial

Immunosuppression1 trial

Cardiac Transplant1 trial

Cardiac Allograft Vasculopathy1 trial

Allogeneic Hematopoietic Cell Transplant1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News